Bausch Health Companies Inc. Stock News

Shares of Bausch Health Companies Inc. surged 2.9% toward a five-year high in premarket trading Wednesday, after the pharmaceuticals and medical devices company said it reached an agreement with billi

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bausch Health: Valued Significantly Below Sum Of The Parts And Generating Activist Interest

Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company's largest shareholder to

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccine

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the last five years is 131.9%.

The shares of Bausch Health Companies Inc (NYSE:BHC) are up 4.3% at $31.41 at last check, after Icahn Capital LP reported a 7.8% stake in the pharmaceutical concern, which is the equivalent of 27.8 mi

Bausch Health stock got an added boost Friday after billionaire investor Carl Icahn disclosed a 7.8% stake in the pharmaceutical and medical device company.

Shares of Bausch Health Companies Inc. rallied 5.8% in premarket trading Friday, putting them on track for a 10th straight gain, after billionaire activist investor Carl Icahn disclosed that he had a

The healthcare company released a positive preliminary update for the fourth quarter.

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 39th Annual JP Morgan Healthcare Conference (Transcript)

Bausch Health Corp. shares gained more than 5% in after-hours trading Tuesday after the company announced that its annual revenue will come in higher than its guidance. Bausch Health, formerly known a

Bausch Health Cos. Inc. said Tuesday it is planning to pay down another $275 million of senior secured term loans, using cash on hand and cash generated from operations.

No Debt Maturities or Mandatory Amortization Payments Will Be Due Until 2024 Bausch Health Will Repay Approximately $900 Million of Debt in 2020 LAVAL, QC, Dec. 29, 2020 /PRNewswire/ -- Bausch Health